Copyright
©The Author(s) 2022.
World J Clin Cases. Jul 16, 2022; 10(20): 6759-6768
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6759
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6759
Figure 1 Semaglutide-mechanisms of action with potential benefits for metabolically associated fatty liver disease/non-alcoholic fatty liver disease patients with increased hepatic and extrahepatic (cardiovascular) risk.
FFA: Free fatty acids.
- Citation: Cigrovski Berkovic M, Rezic T, Bilic-Curcic I, Mrzljak A. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum? World J Clin Cases 2022; 10(20): 6759-6768
- URL: https://www.wjgnet.com/2307-8960/full/v10/i20/6759.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i20.6759